pentobarbital will lessen the extent or influence of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic outcome of elbasvir/grazoprevir might be decreased if coadministered with strong CYP3A inducers and is also thus contraindicated.pentobarbital decreases amounts of vandetanib by impacti